Skip to contents

Aaron S. Kesselheim, MD, JD, MPH
Associate Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Phar Epid & Phar Econ
75 Francis Street
Boston, MA 02115

Research Location: One Brigham Circle


Edit Profile


Research Narrative:

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Dr. Kesselheim leads the Program On Regulation, Therapeutics, And Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL conducts research on empirical and normative research in legal, ethical, and policy issues regarding the development, approval, and evidence-based use of drugs, devices, vaccines, procedures, and diagnostics. Particular areas of focus include regulation, intellectual property, and comparative effectiveness. These topics are addressed through a variety of descriptive, qualitative, and quantitative methodologies.


Education:
Harvard School of Public Health, 2007, MPH
University of Pennsylvania School of Medicine, 2002, MD
University of Pennsylvania Law School, 2002, JD

Publications (Pulled from Harvard Catalyst Profiles):

1. Growdon ME, Sacks CA, Kesselheim AS, Avorn J. Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers. JAMA Intern Med. 2019 Aug 05.

2. Li DG, Najafzadeh M, Kesselheim AS, Mostaghimi A. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis. BMJ. 2019 07 17; 366:l4257.

3. Dave CV, Patorno E, Franklin JM, Huybrechts K, Sarpatwari A, Kesselheim AS, Bateman BT. Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. J Gen Intern Med. 2019 Jul 15.

4. Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Saf. 2019 Jul 13.

5. Sarpatwari A, Kesselheim AS. Reforming the Orphan Drug Act for the 21st Century. N Engl J Med. 2019 Jul 11; 381(2):106-108.

6. Feldman WB, Hey SP, Franklin JM, Kesselheim AS. Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys. JAMA Netw Open. 2019 Jul 03; 2(7):e197591.

7. Stern AD, Pietrulla F, Herr A, Kesselheim AS, Sarpatwari A. The Impact Of Price Regulation On The Availability Of New Drugs In Germany. Health Aff (Millwood). 2019 Jul; 38(7):1182-1187.

8. Kramer DB, Kesselheim AS. Trust and transparency in medical device regulation. BMJ. 2019 06 18; 365:l4166.

9. Dave CV, Brill G, Kesselheim AS. Changes in Price for Generic Drugs in the USA, 2008-2016. J Gen Intern Med. 2019 May 07.

10. Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing. JAMA Intern Med. 2019 May 01; 179(5):707-709.